|【英語タイトル】Generics in Spain|
SummaryGenerics in Spain industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Spain
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Spain
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Spain generics market with five year forecasts by both value and volume
Essential resource for top-line data and analysis covering the Spain generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Reasons To Buy
- What was the size of the Spain generics market by value in 2016?
- What will be the size of the Spain generics market in 2021?
- What factors are affecting the strength of competition in the Spain generics market?
- How has the market performed over the last five years?
- How large is Spain’s generics market in relation to its regional counterparts?
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the ‘generic-eligible’ market, are not included.
The Spanish generics market is expected to generate total revenues of $3.1bn in 2016, representing a compound annual growth rate (CAGR) of 6.8% between 2012 and 2016.
Market consumption volume is forecast to increase with a CAGR of 4.9% between 2012 and 2016, to reach a total of 81.2% of total pharma volume in 2016.
In Spain there is a great deal of difference in per capita public pharmaceutical expenditure. There is also a big difference in terms of prescriptions per capita. This is largely caused by differences in the age of its population in different areas. However, this gap is slowly closing.
Market value forecast
Market volume forecast
Market value forecast
Market volume forecast
Five Forces Analysis
Threat of substitutes
Degree of rivalry
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Related MarketLine research
Table 1: Spain generics market value: $ billion, 2012-16(e)
Table 2: Spain generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Spain generics market geography segmentation: $ billion, 2016(e)
Table 4: Spain generics market value forecast: $ billion, 2016-21
Table 5: Spain generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Esteve Group: key facts
Table 7: Mylan Inc.: key facts
Table 8: Mylan Inc.: key financials ($)
Table 9: Mylan Inc.: key financial ratios
Table 10: Sandoz International GmbH: key facts
Table 11: Teva Pharmaceutical Industries Limited: key facts
Table 12: Teva Pharmaceutical Industries Limited: key financials ($)
Table 13: Teva Pharmaceutical Industries Limited: key financial ratios
Table 14: Spain size of population (million), 2012-16
Table 15: Spain gdp (constant 2005 prices, $ billion), 2012-16
Table 16: Spain gdp (current prices, $ billion), 2012-16
Table 17: Spain inflation, 2012-16
Table 18: Spain consumer price index (absolute), 2012-16
Table 19: Spain exchange rate, 2012-16
Figure 1: Spain generics market value: $ billion, 2012-16(e)
Figure 2: Spain generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Spain generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Spain generics market value forecast: $ billion, 2016-21
Figure 5: Spain generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Spain, 2016
Figure 7: Drivers of buyer power in the generics market in Spain, 2016
Figure 8: Drivers of supplier power in the generics market in Spain, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Spain, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Spain, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Spain, 2016
Figure 12: Mylan Inc.: revenues and profitability
Figure 13: Mylan Inc.: assets and liabilities
Figure 14: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 15: Teva Pharmaceutical Industries Limited: assets and liabilities